Design and Synthesis of Some New Quinoxaline-1,2,4-triazole-3-amide Conjugates as Anticancer Agents

The newly synthesized quinoxaline-1,2,4-triazole-3-amide conjugates through a multistep method. The prepared compounds were screened for their anticancer activity against secreted human cancer cell lines such as DU-145 (prostate), MCF-7 (breast), and A549 (lung) by applying the MTT method, and the standard drug etoposide was used as a reference drug. The activity results show that two compounds, namely 3,5-dimethoxy-N-(5-{[2-oxoquinoxalin-1(2H)-yl]methyl}-4H-1,2,4-triazol-3-yl)benzamide and 4-methoxy-N-(5-{[2-oxoquinoxalin-1(2H)-yl]methyl}-4H-1,2,4-triazol-3-yl)benzamide exhibited more potent activity than the standard drug. Whereas, two compounds, 3-methoxy-N-(5-{[2-oxoquinoxalin-1(2H)-yl]methyl}-4H-1,2,4-triazol-3-yl)benzamide, and 3,4-dimethoxy-N-(5-{[2-oxoquinoxalin-1(2H)-yl]methyl}-4H-1,2,4-triazol-3-yl)benzamide showed very similar activity against tested cell lines to that of the standard drug IC₅₀ value. The in vitro tyrosine kinase EGFR inhibitory activity results indicate that two compounds, 3,5-dimethoxy-N-(5-{[2-oxoquinoxalin-1(2H)-yl]methyl}-4H-1,2,4-triazol-3-yl)benzamide and 4-methoxy-N-(5-{[2-oxoquinoxalin-1(2H)-yl]methyl}-4H-1,2,4-triazol-3-yl)benzamide exhibited more activity than the standard drug etoposide.